Combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with lower all-cause mortality compared to SGLT-2 inhibitors alone in type 2 diabetes.
Does combination therapy with SGLT-2 inhibitors and GLP-1 RAs reduce all-cause mortality compared with SGLT-2 inhibitors alone in individuals with type 2 diabetes?
In a real-world cohort of patients with type 2 diabetes, concurrent use of SGLT-2 inhibitors and GLP-1 RAs was associated with lower all-cause mortality compared to SGLT-2 inhibitor therapy alone.
In this large real-world cohort, combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with a lower hazard of all-cause mortality, while most secondary cardiorenal outcomes showed generally favourable but imprecise estimates. These findings suggest that sustained concurrent use of both drug classes may offer meaningful clinical benefits in routine practice, although residual confounding cannot be fully excluded.
Maier et al. (2026) studied this question. Combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with lower all-cause mortality compared to SGLT-2 inhibitors alone in type 2 diabetes.